Skip to content

Increasing COVID-19 Vaccine Uptake in Developing Countries (Bihar)

Increasing COVID-19 Vaccine Uptake in Developing Countries (Bihar)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05225064
Enrollment
114512
Registered
2022-02-04
Start date
2022-01-19
Completion date
2022-04-27
Last updated
2022-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaccination Refusal

Keywords

COVID-19, vaccination, masks, incentives

Brief summary

Working with governments in Bihar, India, we will evaluate a number of mechanisms to increase vaccine uptake. These include household vaccination visits instead of community vaccination clinic.monetary and non-monetary incentives, and concurrent mask promotion. This ClinicalTrials entry contains results only for the study in Bihar.

Detailed description

The goal of the study is to identify strategies that best promote and support COVID vaccine uptake in developing countries, we propose to test a range of scalable social and behavioural interventions. This could help policy makers design and employ interventions that are effective. This is especially valuable in resource constrained contexts where funds and institutional resources can be diverted towards interventions that have proven to work. In Bihar the intervention will be village-level social mobilization involving community promotion, including in-person vaccine reinforcement, and household-level social mobilization. Some treatment villages will receive household- level interventions with varying intensity (different proportion of households will be visited). There will also an accompanying mask distribution campaign during household visits where the importance of mask-wearing as a complement to vaccine use will be explained. This ClinicalTrials entry contains results only for the study in Bihar.

Interventions

BEHAVIORALIncentives to be vaccinated

Individuals will be provided with a guaranteed cash payment, entry into a cash lottery, or guaranteed gift of food if they are vaccinated

DEVICEMask

Individuals are given cloth masks

BEHAVIORALEncouragement to wear a mask

Individuals who are not wearing masks over their mouth and nose are stopped in public places and encouraged to wear a mask

BEHAVIORALVaccination made more convenient

Vaccines are conducted at the household-level rather than the village-level

BEHAVIORALSocial mobilization campaign to be vaccinated

Village-level social mobilization campaign to be vaccinated

Sponsors

University of Connecticut
CollaboratorOTHER
Lahore University of Management Sciences
CollaboratorOTHER
University of California, Berkeley
CollaboratorOTHER
Innovations for Poverty Action
CollaboratorOTHER
Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

The investigator and outcome assessor will be blind to study arm assignment. Due to the nature of the intervention, participants and care providers will not be blind to intervention assignment; however they are likely to be unaware of intervention components because they are not expect to communicate with those who are assigned to a different intervention arm

Intervention model description

There are five arms. Arm 1: Control; Arm 2: Village-level vaccine clinics with monetary, non-monetary, or no incentive; Arm 3: Household-level vaccination with monetary, non-monetary, or no incentive; Arm 4: Mask promotion; Arm 5: Village-level vaccine clinics and mask promotion

Eligibility

Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Lives in study village

Exclusion criteria

* Does not live in study village

Design outcomes

Primary

MeasureTime frameDescription
Percent of individuals who receive the first, second, or third dose of covid vaccineup to 4 weeks (endline may vary depending on estimated uptake rates)Prevalence of vaccination with difference doses

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026